Immune responses to BK and JC viruses in immunocompromised patients

Future Virology

Volumn 2, Issue 3, 2007, Pages 255-266

  Lacey, Simon F ^a   Zhou, Wendi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

BK virus; Cidofovir; Cytotoxic T lymphocyte; Hemorrhagic cystitis; JC virus; Natalizumab; Nephropathy; Polyomaviruses; Progressive multifocal leukoencephalopathy; Rituxumab

Indexed keywords

ALPHA INTERFERON; BETA1 INTERFERON; CIDOFOVIR; CYTARABINE; NATALIZUMAB; RITUXIMAB; STEROID; TOPOTECAN;

AIDS PATIENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; BK VIRUS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; HEMORRHAGIC CYSTITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFECTION SENSITIVITY; JC VIRUS; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY GRAFT; LONG TERM CARE; MULTIPLE SCLEROSIS; NEPHROTOXICITY; OLIGODENDROGLIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIREMIA; VIRUS INFECTION; VIRUS LOAD;

BK POLYOMAVIRUS; JC POLYOMAVIRUS; POLYOMAVIRUS;

EID: 34249282393     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.3.255     Document Type: Review

References (80)

1. Padgett BL, Walker DL: New human papovaviruses. Prog. Med. Virol. 22, 1-35 (1976).
2. Allander T, Andreasson K, Gupta S et al.: Identification of a third human polyomavirus. J. Virol. (2007) (Epub ahead of print).
3. White MK, Gordon J, Reiss K et al.: Human polyomaviruses and brain tumors. Brain Res. Brain Res. Rev. 50, 69-85 (2005).
4. Knowles WA, Pipkin P, Andrews et al.: Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 71, 115-123 (2003).
5. Hamilton RS, Gravell M, Major EO: Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J. Clin. Microbiol. 38, 105-109 (2000).
6. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J: Seroepidemiology of the human polyomaviruses. J. Gen. Virol. 84, 1499-1504 (2003).
7. Jameson SC, Bevan MJ: Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs. Eur. J. Immunol. 22, 2663-2667 (1992).
8. Ling PD, Lednicky JA, Keitel WA et al.: The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J. Infect. Dis. 187, 1571-1580 (2003).
9. Brooks BR, Walker DL: Progressive multifocal leukoencephalopathy. Neurol. Clin. 2, 299-313 (1984).
10. Power C, Gladden JG, Halliday W: AIDS-and non-AIDS-related PML association with distinct P53 polymorphism. Neurology 54, 743-746 (2000).
11. Antinori A, Cingolani A, Lorenzini P et al.: Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J. Neurovirol. 9(Suppl. 1), 47-53 (2003).
12. Marra CM, Rajicic N, Barker DE et al.: A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16, 1791-179 (2002).
13. Gasnault J, Kousignian P, Kahraman M et al.: Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J. Neurovirol. 7, 375-381 (2001).
14. Berenguer J, Miralles P, Arrizabalaga J et al.: Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin. Infect. Dis. 36, 1047-1052 (2003).
15. Osorio S, de La Camera R, Golbano N et al.: Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant. 30, 963-966 (2002).
16. Aksamit AJ: Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J. Neurovirol. 7, 386-390 (2001).
17. Hall CD, Dafni U, Simpson D et al.: Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N. Engl. J. Med. 338, 1345-1351 (1998).
18. Geschwind MD, Skolasky RI, Royal WS, McArthur JC: The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J. Neurovirol. 7, 353-357 (2001).
19. Miralles P, Berenguer J, Lacruz C et al.: Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15, 1900-1902 (2001).
20. Royal W 3rd, Dupont B, McGuire D et al.: Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J. Neurovirol. 9, 411-419 (2003).
21. Knowles WA: The epidemiology of BK virus and the occurrence of antigenic and genomic subtypes. In: Human Polyomaviruses: Molecular and Clinical Perspectives. Khalili K, Stoner GL (Eds.). Wiley-Liss, USA (2001).
22. Chesters PM, Heritage J, McCance DJ: Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J. Infect. Dis. 147, 676-684 (1983).
23. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP: Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 53, 263-276 (2002).
24. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL: Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 98, 1971-1978 (2001).
25. Hirsch HH, Steiger J: Polyomavirus BK. Lancet Infect. Dis. 3, 611-623 (2003).
26. Cosio FG, Amer H, Grande JP, Larson TS, Stegall MD, Griffin MD: Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 83, 411-416 (2007).
27. Funk GA, Steiger J, Hirsch HH: Rapid dynamics of polyomavirus type BK in renal transplant recipients. J. Infect. Dis. 193, 80-87 (2006).
28. Nickeleit V, Hirsch HH, Binet IF et al.: Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J. Am. Soc. Nephrol. 10, 1080-1089 (1999).
29. Randhawa PS, Demetris AJ: Nephropathy due to polyomavirus type BK. N. Engl. J. Med. 342, 1361-1363 (2000).
30. Nickeleit V, Hirsch HH, Zeiler M et al.: BK-virus nephropathy in renal transplants-tubular necrosis MHC-class II expression and rejection in a puzzling game. Nephrol. Dial. Transplant. 15, 324-332 (2000).
31. Hirsch HH, Brennan DC, Drachenberg CB et al.: Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79, 1277-1286 (2005).
32. Hirsch HH, Knowles W, Dickenmann M et al.: Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N. Engl. J. Med. 347, 488-496 (2002).
33. Bohl DL, Storch GA, Ryschkewitsch C et al.: Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am. J. Transplant. 5, 2213-2221 (2005).
34. Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP: Polyomavirus nephropathy in pediatric kidney transplant recipients. Am. J. Transplant. 4, 2109-2117 (2004).
35. Ginevri F, De Santis R, Comoli P et al.: Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 75, 1266-1270 (2003).
36. Hariharan S, Cohen EP, Vasudev B et al.: BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am. J. Transplant. 5, 2719-2724 (2005).
37. Randhawa PS, Gupta G, Vats A, Shapiro R, Viscidi RP: Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin. Vaccine Immunol. 13, 1057-1063 (2006).
38. Guillaume B, Sindic CJ, Weber T Progressive multifocal leukoencephalopathy: simultaneous detection of JCV DNA and anti-JCV antibodies in the cerebrospinal fluid. Eur. J. Neurol. 7, 101-106 (2000).
39. Weber T, Trebst C, Frye S et al.: Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J. Infect. Dis. 176, 250-254 (1997).
40. Weber F, Goldmann C, Kramer M et al.: Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann. Neurol. 49, 636-642 (2001).
41. Berner B, Krieter DH, Rumpf KW et al.: Progressive multifocal leukoencephalopathy in a renal transplant patient diagnosed by JCV-specific DNA amplification and an intrathecal humoral immune response to recombinant virus protein 1. Nephrol. Dial. Transplant. 14, 462-465 (1999).
42. + progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J. Immunol. 168, 499-504 (2002).
43. Du Pasquier RA, Kuroda MJ, Schmitz JE et al.: Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1 (p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J. Virol. 77, 11918-11926 (2003).
44. Du Pasquier RA, Schmitz JE, Jean-Jacques J et al.: Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J. Virol. 78, 10206-10210 (2004).
45. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ: A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127, 1970-1978 (2004).
46. + T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J. Virol. (2007).
47. Wuthrich C, Kesari S, Kim WK et al.: Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J. Neurovirol. 12, 116-128 (2006).
48. Miller DH, Khan OA, Sheremata WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
49. Polman CH, O'Connor PW, Havrdova E et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
50. Gordon FH, Lai CW, Hamilton MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121, 268-274 (2001).
51. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353, 369-374 (2005).
52. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natatizumab. N. Engl. J. Med. 353, 375-381 (2005).
53. Van Assche G, Van Ranst M, Sciot R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
54. Yousry TA, Major EO, Ryschkewitsch C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933 (2006).
55. Browning JL: B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5, 564-576 (2006).
56. Goldberg SL, Pecora AL, Alter RS et al.: Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99, 1486-1488 (2002).
57. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM: Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100, 1104-1105 (2002).
58. Steurer M, Clausen J, Gotwald T et al.: Progressive multifocal leukoencephalopathy after allogencic stem cell transplantation and posttransplantation rituximab. Tansplantation 76, 435-436 (2003).
59. Niino M, Bodner C, Simard ML et al.: Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 59, 748-754 (2006).
60. Stuve O, Marra CM, Bax-Or A et al.: Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63, 1383-1387 (2006).
61. Comoli P, Azzi A, Maccario R et al.: Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 78, 1229-1232 (2004).
62. Comoli P, Binggeli S, Ginevri F, Hirsch HH: Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transpl. Infect. Dis. 8, 86-94 (2006).
63. Hammer MH, Brestrich G, Andree H et al.: HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am. J. Transplant. 6, 625-631 (2006).
64. Binggeli S, Egli A, Schaub S et al.: Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am. J. Tansplant. 7, 1-9 (2007).
65. Lacey SF: BK viral loads and immune monitoring in renal transplant recipients. American Journal of Transplantation Editorial, 7, (2007).
66. Krymskaya L, Sharma MC, Martinez J et al.: Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC Virus VP1 polypeptides. J. Virol. 79, 11170-11178 (2005).
67. Sharma MC, Zhou W, Martinez J et al.: Cross-reactive CTL recognizing two HLAA*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. Virology 350, 128-136 (2006).
68. Chen Y, Trofe J, Gordon J et al.: Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J. Virol. 80, 3495-3505 (2006).
69. + BKV-seropositive donors. J. Transl. Med. 4, 47 (2006).
70. +) T cells sensitized to bk virus large t antigen in healthy volunteers and kidney transplant recipients. Hum. Immunol. 67, 298-302 (2006).
71. Li J, Melenhorst J, Hensel N et al.: T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J. Gen. Virol. 87, 2951-2960 (2006).
72. Awadalla Y, Randhawa P, Ruppert K, Zeevi A, Duquesnoy RJ: HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am. J. Transplant. 4, 1691-1696 (2004).
73. Drachenberg CB, Papadimitriou JC, Mann D, Hirsch HH, Wali R, Ramos E: Negative impact of human leukocyte antigen matching in the outcome of polyomavirus nephropathy. Transplantation 80, 276-278 (2005).
74. Comoli P, Basso S, Azzi A et al.: Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J. Am. Soc. Nephrol. 14, 3197-3204 (2003).
75. Haque T, Wilkie GM, Taylor C et al.: Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436-442 (2002).
76. Khanna R, Bell S, Sherritt M et al.: Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96, 10391-10396 (1999).
77. Comoli P, Labirio M, Basso S et al.: Infusion of autologous Epstein-Barr virus (EBV)- specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99, 2592-2598 (2002).
78. Perruccio K, Tosti A, Burchielli E et al.: Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 106, 4397-4406 (2005).
79. + T cells. Blood 107, 4781-4789 (2006).
80. Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ: Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 19, 2069-2076 (2005).